The rate of growth is above projections/guidance. "Revise FY24 revenue guidance to US$36m-40m" is conservative. Hit it or exceed and the money flow is just the start. As a Veteran myself I liked "direct sales of BlastXTM to Long Term Care Centres and Veterans Affairs clinics"
In Australia we have very ultra conservative Doctors. I predict/assume they will be dragged to use NXS innovations in surgery a lot more quickly once legal case(S) by those who get infections get paid out much more as the hospital/surgical infections which would have been avoided IF they had used XPERIENCEtm during surgery and BlastX post surgery as I did four years ago.
Had my leg been chopped off from the nasty infection I had I would have been unable to do that 4 years ago. I only needed the 3rd round of surgery where I used XPERIENCE during surgery and BlastX post surgery due to the infection in my 2nd surgery! It cost me a year delay in my recovery! Compensation cases for avoidable infections are highly likely! A few cases will be enough to drag the slow change in our usually very smart medical systems which are happily risk adverse.
• FY23 Revenue of US$22.2m, up 89.4% on pcp2 with 2H FY23 revenue of US$12.1m
in line with 2H FY23 guidance of US$12m-14m provided in October 2023.
• 4Q FY23 Product Sales of US$7.1m, up 123.5% on pcp reflecting the focus on direct
product sales and introduction of DME3 structure in October 2022.
• 4Q FY23 Direct Product Sales of US$5.6m, up 164.7% on pcp: 79% of product sales.
• Closing cash balance of US$9.2m (30 Sept 2023: US$12.4m) and no debt.
• Reaffirm FY24 guidance to be EBITDA and cashflow positive in 2H FY24.
• Revise FY24 revenue guidance to US$36m-40m. (Previous guidance was for FY24
revenue growth of over 85% year-on-year).
- Forums
- ASX - By Stock
- Ann: Appendix 4C & Quarterly Activity Report - 31 December 2023
The rate of growth is above projections/guidance. "Revise FY24...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NXS (ASX) to my watchlist
(20min delay)
|
|||||
Last
26.0¢ |
Change
0.015(6.12%) |
Mkt cap ! $75.84M |
Open | High | Low | Value | Volume |
25.5¢ | 26.5¢ | 24.5¢ | $20.20K | 79.07K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 9313 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 24500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 9313 | 0.250 |
4 | 103400 | 0.245 |
3 | 87613 | 0.240 |
2 | 7939 | 0.230 |
1 | 20000 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 24500 | 1 |
0.265 | 11320 | 1 |
0.270 | 67785 | 2 |
0.275 | 12350 | 1 |
0.280 | 3571 | 1 |
Last trade - 15.30pm 20/06/2024 (20 minute delay) ? |
Featured News
NXS (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Chairman
Nick Poll
Executive Chairman
Previous Video
Next Video
SPONSORED BY The Market Online